Positive data from Phase 2 MaGic trial for claseprubart in generalized Myasthenia Gravis was presented, showing support for potential 300mg/2mL Q4W dosing. Phase 3 gMG trial planned with two treatment arms vs. placebo to begin in 2026. New preclinical data also highlights the benefits of upstream complement inhibition. A virtual industry forum replay is available. Following AANEM, Dianthus Therapeutics shared data from the Phase 2 MaGic trial, including a subgroup analysis and in vitro data comparing upstream vs. downstream complement inhibition. Plans for Phase 3 trials in gMG and other autoimmune disorders are underway, as claseprubart shows promise in transforming autoimmune disease treatment.

Read more at GlobeNewswire: Dianthus Therapeutics Highlights New Claseprubart Data